Uncategorized
Clinical Science Award 2021 for GYG
Congrats to Georg Györi receiving the Clinical Science Award 2021 from the Austrian Transplant Society
Download multiple smart phone Apps for informational purposes to make your daily clinical life easier
Get an overview about our current projects and recent findings
Explore our News section for updates on our most recent findings and highlights of TELLVienna
Things we are proud of ...
You want do support our research to improve patients care. Click here
Find what will soon be available for you in the clinics
Liver resection is considered the only curative treatment option for several neoplastic entities of the liver. Despite substantial improvements in surgical techniques and peri-operative care, post-operative failure of liver regeneration and concomitant liver dysfunction remain an important concern after partial hepatectomy. In hepatobiliary surgery, this is of major clinical relevance as patient outcome correlates with the potential of the remnant liver to regenerate. In particular, postoperative liver failure represents a frequently fatal postoperative complication with very limited therapeutic options. In this context, it is of crucial importance to understand the complex process of liver regeneration. Indeed, the potential of the liver to regenerate after resection is unique and orchestrated by a combination of highly redundant effector molecules, as blockage of a single molecule only delays but does not stop the process.. It is known that a variety of bioactive molecules are involved in liver regeneration. In the past decades, essential insights in mechanisms of hepatic regeneration have been unraveled and several mediators of these mechanisms have been explored in detail. Furthermore, thrombocytes have been found to play a crucial role, not only during the initiation period, but throughout all phases of liver regeneration. In this context, hepatobiliary surgery struggles with two major obstacles: i) to identify patients at risk of postoperative liver dysfunction and concomitant major, potentially lethal, complications prior to surgery; ii) to identify patients with highly aggressive disease, that will not benefit from liver resection due to rapid recurrence of the tumor. In both cases surgery should be omitted as there is no benefit for these patients. However, to date no reliable marker is available to predict patient outcome and postoperative tumor relapse.
Main research objectives of the group:
a) Molecular mechanisms of liver regeneration and potential treatment targets:
– Identification of central regulators and processes involved in the initiation of liver regeneration.
– Characterization of regulatory mechanisms and thereby identification of novel therapeutic targets to support the regenerative capacity after liver resection as well as to improve our understanding of the pathophysiological processes involved in liver regeneration.
b) Predictive and prognostic markers for liver regeneration and primary and secondary liver cancer:
– Identification of clinical and experimental markers of liver regeneration which reflect the prognosis of regenerative capability and therefore the postoperative outcome after liver surgery, to ultimately tailor surgical strategy to each individual patient and thereby avoid potentially fatal complications.
– Quantification of tumor aggressiveness using clinical and experimental markers to predict early disease recurrence, to spare unnecessary surgery in patients that will not benefit from tumor resection.
c) Cancer development:
– Identification of the role of platelets and immune cells and their interaction during the development of liver cancer and progression.
d) Gender and Diversity
Patrick is a consultant surgeon at the Medical University of Vienna with a prime interest in liver and colorectal cancer surgery. He further is a physician scientist and PI of TELLVienna focusing on translational research with a clear reference to improving patients care.
David joined TELLVienna in 2014. His work initially focused on preoperative risk evaluation in liver resection and transplantation. After the completion of his medical degree in 2019 he enrolled the MD-PhD program. Currently he is focused on platelet mediated liver regeneration working on murine models of partial hepatectomy.
Jennifer is focusing on primary cell isolation and specialised on human hepatocytes. Jennifer joined the team in September of 2017. Currently she is doing research on the molecular mechanism of pathways affecting liver regeneration. She is interested in establishing new primary cell lines and different culture models.
Philipp is a surgical resident with a specific interest in liver pathophysiology. His main field of research currently focuses on metabolomics in liver regeneration and cancer.
Fascinated by the prospect of combining general surgery and research, Benedikt joined the Team in october of 2017. His field of work includes maintenance of broad data and isolating DNA. Currently, his research lays focus on transplant surgery.
Georg is a consultant surgeon at the Medical University of Vienna surgical department. After completion of his fellowship training in HPB and Liver-Transplant Surgery at the University Hospital Zurich in 2016, his clinical focus is primarily on liver transplantation. Main research interests are pre- and perioperative risk assessment as well as connecting liver transplant research to existing translational projects at the TELL Vienna.
Jonas is a medical student with a focus on visceral surgery since his first year of university. He is interested in translational liver research, especially in partial hepatectomy mouse models and translational research. Jonas’s current expertise lies in systematic biobanking, partial hepatectomy in mice and database care.
Sina joined the lab during his first year of medical school in 2018. He is interested in molecular signaling pathways involved in liver regeneration, and the role that liver progenitor cells play in this process. His prime expertise till now lies in systematic biobanking and immunfluorescense based imaging.
Congrats to Georg Györi receiving the Clinical Science Award 2021 from the Austrian Transplant Society
Finally after months of work our first App is officially in the APP store available for iPhone and Android. Preoperative risk assessment prior to liver resection – next generation! Remember the last patient you lost Read more…
2020 TELLVienna we received the again the Theodor Billroth award as the highest Austrian research award achievable.
https://aasldpubs.onlinelibrary.wiley.com/doi/epdf/10.1002/hep.31047
Congrats to Jan Philipp Jonas to making the first place of the young surgeons awards at the this years annual meeting of the Austrian Society of Surgery
The jury of the the Young Surgeons Award from the Austrian Society of Surgery could not be given to only one presenter. Proud to see the TELLVienna group beeing awarded this honor.
Using our strength as a group to do something aside from research. For the Vienna city marathon we decided to run for a viennese organization that supports home care for children with cancer. With the Read more…
Philipp just presented our first explorative data on systematic metabolomic analyses of patients samples at the German surgical congress – exciting new findings to better understand the process of liver regeneration in humans
Great to see 12 young people discussing and elaborating new ideas. After an exciting winter hike we spend 3 days of brainstorming and learning from each other – truly inspiring + great new ideas
David Pereyra received the best poster award at this years 11th EFR (european federation for colorectal cancer) congress with our work on Osteopontin and its association with disease recurrence after liver resection. TELLvienna congratulates to Read more…
ILC/EASL 2019 Excited to see major interest in our work @ILC2019, EASL in Vienna. Thank you @Medizin Medien Austria for featuring our results and surgical highlights of the congress with an interview – great pleasure. Read more…
Ever found it puzzling that a patient with more than 12 months of neoadjuvant chemotherapy flies trough postoperative recovery after major liver resection without any signs of chemotherapy associated steatohepatitis (CASH) on histology, while some Read more…
Remember your last patient developing liver failure after liver resection? Proofs of our recent work on miRNAs in liver surgery are out now demonstrating that miRNAs are sensitive markers for preoperative liver function and predict Read more…
Ever found it puzzling that a patient with more than 12 months of neoadjuvant chemotherapy flies trough postoperative recovery after major liver resection without any signs of chemotherapy associated steatohepatitis (CASH) on histology, while some Read more…
Translational and Experimental Liver Laboratory - TELLVIENNA
Medical University of Vienna
A-1090 Vienna, Waehringer Guertel 18-20
Anna Spiegel Forschungsgebaeude, 25.05.31
Austria
Assoc. Prof. Patrick Starlinger, MD, PhD
Tel: 0043-1-40400-56210, 0043-1-40400-73526